A further step has been the development of trispecific nanobodies targeting PD-L1, 4-1BB, and NKG2A/TIGIT, which simultaneously activate NK and CD8+ T cells, suppressing tumor organoids and xenografts in humanized mouse models (251). This evidence concerns the gene CD8A and neoplasm.